Terms: = Breast cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
41 results:
1. Insight into the design of fgfr4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract] [Full Text] [Related]
2. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract] [Full Text] [Related]
3. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
4. N6-methyladenosine regulated fgfr4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.
Zou Y; Zheng S; Xie X; Ye F; Hu X; Tian Z; Yan SM; Yang L; Kong Y; Tang Y; Tian W; Xie J; Deng X; Zeng Y; Chen ZS; Tang H; Xie X
Nat Commun; 2022 May; 13(1):2672. PubMed ID: 35562334
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the treatment of Hepatocellular Carcinoma.
Zhong Z; Shi L; Fu T; Huang J; Pan Z
J Med Chem; 2022 May; 65(10):7278-7295. PubMed ID: 35549181
[TBL] [Abstract] [Full Text] [Related]
6. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.
Silvestri M; Dugo M; Vismara M; De Cecco L; Lanzoni D; Vingiani A; Folli S; De Santis MC; de Braud F; Pruneri G; Di Cosimo S; Cappelletti V
Sci Rep; 2022 Jan; 12(1):1470. PubMed ID: 35087134
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract] [Full Text] [Related]
8. Effects of fgfr4 G388R, V10I polymorphisms on the likelihood of cancer.
Peng T; Sun Y; Lv Z; Zhang Z; Su Q; Wu H; Zhang W; Yuan W; Zuo L; Shi L; Zhang LF; Zhou X; Mi Y
Sci Rep; 2021 Jan; 11(1):1373. PubMed ID: 33446698
[TBL] [Abstract] [Full Text] [Related]
9. fgfr4 Gly388Arg Polymorphism Affects the Progression of Gastric cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract] [Full Text] [Related]
10. fgfr4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract] [Full Text] [Related]
11. fgfr4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract] [Full Text] [Related]
12. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract] [Full Text] [Related]
13. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
[TBL] [Abstract] [Full Text] [Related]
14. Rhynchosia rufescens AgNPs enhance cytotoxicity by ROS-mediated apoptosis in MCF-7 cell lines.
Khader SZA; Syed Zameer Ahmed S; Ganesan GM; Mahboob MR; Vetrivel M; Sankarappan M; Manickam P
Environ Sci Pollut Res Int; 2020 Jan; 27(2):2155-2164. PubMed ID: 31773523
[TBL] [Abstract] [Full Text] [Related]
15. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Gluz O; Kolberg-Liedtke C; Prat A; Christgen M; Gebauer D; Kates R; Paré L; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Pelz E; Nitz U; Kreipe HH; Harbeck N
Int J Cancer; 2020 Jan; 146(1):262-271. PubMed ID: 31162838
[TBL] [Abstract] [Full Text] [Related]
17. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
Chen L; Qi H; Zhang L; Li H; Shao J; Chen H; Zhong M; Shi X; Ye T; Li Q
BMC Cancer; 2018 Oct; 18(1):1038. PubMed ID: 30359238
[TBL] [Abstract] [Full Text] [Related]
18. Therapeutics Targeting FGF Signaling Network in Human Diseases.
Katoh M
Trends Pharmacol Sci; 2016 Dec; 37(12):1081-1096. PubMed ID: 27992319
[TBL] [Abstract] [Full Text] [Related]
19. Fibroblast growth factor receptor 4 (fgfr4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract] [Full Text] [Related]
20. Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating fgfr4/FRS2α-ERK1/2 pathway-mediated NF-κB activation.
Guo Y; Ding Y; Zhang T; An H
Phytomedicine; 2016 Mar; 23(3):267-73. PubMed ID: 26969380
[TBL] [Abstract] [Full Text] [Related]
[Next]
